Company news

Immunovant, Inc. news in 2020

Immunovant, Inc.'s news releases, calls and decks from 2020, newest first.

View company

Immunovant Reports Financial Results for the Quarter and Six Months Ended September 30, 2020

November 11, 2020

Immunovant Announces Closing of $200.0 Million Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

September 3, 2020

Immunovant Announces Pricing of Public Offering

September 1, 2020

Immunovant Announces Positive Topline Results from Multi-Center, Placebo-Controlled Phase 2a Trial of IMVT-1401, A Novel Investigational Anti-FcRn Antibody Delivered by Subcutaneous Injection, in Myasthenia Gravis

August 24, 2020

Immunovant Appoints Michael Elliott Chief Scientific Officer

August 23, 2020

Immunovant Reports Financial Results for the Quarter Ended June 30, 2020

August 11, 2020

Immunovant Reports Financial Results for the Quarter and Fiscal Year Ended March 31, 2020 and Announces Plans for Phase 3 Registrational Trial of IMVT-1401 in Myasthenia Gravis

June 28, 2020

Immunovant Announces Redemption of Warrants and Achievement of First Earnout Milestone under Share Exchange Agreement

May 13, 2020

Immunovant Announces Closing of $139.4 Million Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

April 15, 2020

Immunovant Announces Pricing of $121.2 Million Public Offering

April 13, 2020

Immunovant Announces Positive Clinical Results from Ongoing Phase 2a Proof-of-Concept Study of IMVT-1401, A Novel Investigational Anti-FcRn Antibody Delivered by Subcutaneous Injection, in Thyroid Eye Disease

March 29, 2020

Immunovant Reports Financial Results for the Quarter and Nine Months Ending December 31, 2019

February 13, 2020

Immunovant to Present at the 9th Annual SVB Leerink Global Healthcare Conference

February 9, 2020

Decks in 2020